427 related articles for article (PubMed ID: 33208158)
1. ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.
Charmsaz S; Doherty B; Cocchiglia S; Varešlija D; Marino A; Cosgrove N; Marques R; Priedigkeit N; Purcell S; Bane F; Bolger J; Byrne C; O'Halloran PJ; Brett F; Sheehan K; Brennan K; Hopkins AM; Keelan S; Jagust P; Madden S; Martinelli C; Battaglini M; Oesterreich S; Lee AV; Ciofani G; Hill ADK; Young LS
BMC Med; 2020 Nov; 18(1):349. PubMed ID: 33208158
[TBL] [Abstract][Full Text] [Related]
2. ADAM22 as a prognostic and therapeutic drug target in the treatment of endocrine-resistant breast cancer.
Bolger JC; Young LS
Vitam Horm; 2013; 93():307-21. PubMed ID: 23810013
[TBL] [Abstract][Full Text] [Related]
3. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
4. Trans-synaptic LGI1-ADAM22-MAGUK in AMPA and NMDA receptor regulation.
Fukata Y; Hirano Y; Miyazaki Y; Yokoi N; Fukata M
Neuropharmacology; 2021 Aug; 194():108628. PubMed ID: 34089731
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors.
Ohkawa T; Fukata Y; Yamasaki M; Miyazaki T; Yokoi N; Takashima H; Watanabe M; Watanabe O; Fukata M
J Neurosci; 2013 Nov; 33(46):18161-74. PubMed ID: 24227725
[TBL] [Abstract][Full Text] [Related]
6. LGI1 and LGI4 bind to ADAM22, ADAM23 and ADAM11.
Sagane K; Ishihama Y; Sugimoto H
Int J Biol Sci; 2008; 4(6):387-96. PubMed ID: 18974846
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
Varešlija D; Priedigkeit N; Fagan A; Purcell S; Cosgrove N; O'Halloran PJ; Ward E; Cocchiglia S; Hartmaier R; Castro CA; Zhu L; Tseng GC; Lucas PC; Puhalla SL; Brufsky AM; Hamilton RL; Mathew A; Leone JP; Basudan A; Hudson L; Dwyer R; Das S; O'Connor DP; Buckley PG; Farrell M; Hill ADK; Oesterreich S; Lee AV; Young LS
J Natl Cancer Inst; 2019 Apr; 111(4):388-398. PubMed ID: 29961873
[TBL] [Abstract][Full Text] [Related]
8. The LGI1-ADAM22 protein complex in synaptic transmission and synaptic disorders.
Fukata Y; Yokoi N; Miyazaki Y; Fukata M
Neurosci Res; 2017 Mar; 116():39-45. PubMed ID: 27717669
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
10. 14-3-3 proteins stabilize LGI1-ADAM22 levels to regulate seizure thresholds in mice.
Yokoi N; Fukata Y; Okatsu K; Yamagata A; Liu Y; Sanbo M; Miyazaki Y; Goto T; Abe M; Kassai H; Sakimura K; Meijer D; Hirabayashi M; Fukai S; Fukata M
Cell Rep; 2021 Dec; 37(11):110107. PubMed ID: 34910912
[TBL] [Abstract][Full Text] [Related]
11. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission.
Fukata Y; Adesnik H; Iwanaga T; Bredt DS; Nicoll RA; Fukata M
Science; 2006 Sep; 313(5794):1792-5. PubMed ID: 16990550
[TBL] [Abstract][Full Text] [Related]
12. LGI1-ADAM22-MAGUK configures transsynaptic nanoalignment for synaptic transmission and epilepsy prevention.
Fukata Y; Chen X; Chiken S; Hirano Y; Yamagata A; Inahashi H; Sanbo M; Sano H; Goto T; Hirabayashi M; Kornau HC; Prüss H; Nambu A; Fukai S; Nicoll RA; Fukata M
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33397806
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of epilepsy-related ligand-receptor complex LGI1-ADAM22.
Yamagata A; Miyazaki Y; Yokoi N; Shigematsu H; Sato Y; Goto-Ito S; Maeda A; Goto T; Sanbo M; Hirabayashi M; Shirouzu M; Fukata Y; Fukata M; Fukai S
Nat Commun; 2018 Apr; 9(1):1546. PubMed ID: 29670100
[TBL] [Abstract][Full Text] [Related]
14. Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms.
Ramberger M; Berretta A; Tan JMM; Sun B; Michael S; Yeo T; Theorell J; Bashford-Rogers R; Paneva S; O'Dowd V; Dedi N; Topia S; Griffin R; Ramirez-Franco J; El Far O; Baulac S; Leite MI; Sen A; Jeans A; McMillan D; Marshall D; Anthony D; Lightwood D; Waters P; Irani SR
Brain; 2020 Jun; 143(6):1731-1745. PubMed ID: 32437528
[TBL] [Abstract][Full Text] [Related]
15. Adam22 is a major neuronal receptor for Lgi4-mediated Schwann cell signaling.
Ozkaynak E; Abello G; Jaegle M; van Berge L; Hamer D; Kegel L; Driegen S; Sagane K; Bermingham JR; Meijer D
J Neurosci; 2010 Mar; 30(10):3857-64. PubMed ID: 20220021
[TBL] [Abstract][Full Text] [Related]
16. Autosomal dominant lateral temporal epilepsy: absence of mutations in ADAM22 and Kv1 channel genes encoding LGI1-associated proteins.
Diani E; Di Bonaventura C; Mecarelli O; Gambardella A; Elia M; Bovo G; Bisulli F; Pinardi F; Binelli S; Egeo G; Castellotti B; Striano P; Striano S; Bianchi A; Ferlazzo E; Vianello V; Coppola G; Aguglia U; Tinuper P; Giallonardo AT; Michelucci R; Nobile C
Epilepsy Res; 2008 Jul; 80(1):1-8. PubMed ID: 18440780
[TBL] [Abstract][Full Text] [Related]
17. ADAM8 expression in breast cancer derived brain metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.
Conrad C; Götte M; Schlomann U; Roessler M; Pagenstecher A; Anderson P; Preston J; Pruessmeyer J; Ludwig A; Li R; Kamm RD; Ritz R; Carl B; Nimsky C; Bartsch JW
Int J Cancer; 2018 Feb; 142(4):779-791. PubMed ID: 28986926
[TBL] [Abstract][Full Text] [Related]
18. Secretion-Positive LGI1 Mutations Linked to Lateral Temporal Epilepsy Impair Binding to ADAM22 and ADAM23 Receptors.
Dazzo E; Leonardi E; Belluzzi E; Malacrida S; Vitiello L; Greggio E; Tosatto SC; Nobile C
PLoS Genet; 2016 Oct; 12(10):e1006376. PubMed ID: 27760137
[TBL] [Abstract][Full Text] [Related]
19. Absence of mutations in the LGI1 receptor ADAM22 gene in autosomal dominant lateral temporal epilepsy.
Chabrol E; Gourfinkel-An I; Scheffer IE; Picard F; Couarch P; Berkovic SF; McMahon JM; Bajaj N; Mota-Vieira L; Mota R; Trouillard O; Depienne C; Baulac M; LeGuern E; Baulac S
Epilepsy Res; 2007 Aug; 76(1):41-8. PubMed ID: 17681454
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
